Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Polzer

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Rofo : Fortschritte Auf Dem Gebiete Der Rontgenstrahlen Und Der Nuklearmedizin|September 1, 2016
[Not Available]P Polzer, S Weigel
International Journal of Clinical Practice|April 10, 2015
Symptom report and treatment experience of hypogonadal men with and without type 2 diabetes in a United States health planE F Shortridge, P Polzer, P Donga, et al.
International Journal of Clinical Practice|March 29, 2014
Experiences and treatment patterns of hypogonadal men in a U.S. health systemE F Shortridge, P Polzer, P Donga, et al.
The British Journal of Dermatology|February 7, 2018
Efficacy and safety of continuous every-2-week dosing of ixekizumab over 52 weeks in patients with moderate-to-severe plaque psoriasis in a randomized phase III trial (IXORA-P)R G Langley, K Papp, M Gooderham, et al.
Journal of Clinical Psychopharmacology|November 18, 2006
Duloxetine: meta-analyses of suicidal behaviors and ideation in clinical trials for major depressive disorderNayan Acharya, Amy S Rosen, John P Polzer, et al.
The British Journal of Dermatology|September 24, 2019
An indirect comparison of long-term efficacy of every-2-week dosing vs. recommended dosing of ixekizumab in patients who had static Physician's Global Assessment > 1 at week 12K Papp, C Maari, A Cauthen, et al.
European Journal of Paediatric Neurology : EJPN : Official Journal of the European Paediatric Neurology Society|September 22, 2019
Early effective treatment may protect from cognitive decline in paediatric multiple sclerosisA Johnen, C Elpers, E Riepl, et al.
The Journal of Clinical Psychiatry|July 20, 2006
A review of treatment-emergent adverse events during olanzapine clinical trials in elderly patients with dementiaLudmila A Kryzhanovskaya, Dilip V Jeste, Carrie A Young, et al.
Journal of Veterinary Pharmacology and Therapeutics|December 1, 1995
Pharmacokinetics and haematological effects of a single intravenous dose of mitoxantrone in catsD T Kochevar, D L Middendorf, K L Mealey, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Rofo : Fortschritte Auf Dem Gebiete Der Rontgenstrahlen Und Der Nuklearmedizin|September 1, 2016
[Not Available]P Polzer, S Weigel
International Journal of Clinical Practice|April 10, 2015
Symptom report and treatment experience of hypogonadal men with and without type 2 diabetes in a United States health planE F Shortridge, P Polzer, P Donga, et al.
International Journal of Clinical Practice|March 29, 2014
Experiences and treatment patterns of hypogonadal men in a U.S. health systemE F Shortridge, P Polzer, P Donga, et al.
The British Journal of Dermatology|February 7, 2018
Efficacy and safety of continuous every-2-week dosing of ixekizumab over 52 weeks in patients with moderate-to-severe plaque psoriasis in a randomized phase III trial (IXORA-P)R G Langley, K Papp, M Gooderham, et al.
Journal of Clinical Psychopharmacology|November 18, 2006
Duloxetine: meta-analyses of suicidal behaviors and ideation in clinical trials for major depressive disorderNayan Acharya, Amy S Rosen, John P Polzer, et al.
The British Journal of Dermatology|September 24, 2019
An indirect comparison of long-term efficacy of every-2-week dosing vs. recommended dosing of ixekizumab in patients who had static Physician's Global Assessment > 1 at week 12K Papp, C Maari, A Cauthen, et al.
European Journal of Paediatric Neurology : EJPN : Official Journal of the European Paediatric Neurology Society|September 22, 2019
Early effective treatment may protect from cognitive decline in paediatric multiple sclerosisA Johnen, C Elpers, E Riepl, et al.
The Journal of Clinical Psychiatry|July 20, 2006
A review of treatment-emergent adverse events during olanzapine clinical trials in elderly patients with dementiaLudmila A Kryzhanovskaya, Dilip V Jeste, Carrie A Young, et al.
Journal of Veterinary Pharmacology and Therapeutics|December 1, 1995
Pharmacokinetics and haematological effects of a single intravenous dose of mitoxantrone in catsD T Kochevar, D L Middendorf, K L Mealey, et al.
Pageof 1